Clinical Trials Logo

Tolerance clinical trials

View clinical trials related to Tolerance.

Filter by:

NCT ID: NCT05794100 Completed - Tolerance Clinical Trials

Evaluating the Impact of Different Sugar Replacer Combinations on Gastrointestinal Tolerance

Start date: October 11, 2021
Phase: N/A
Study type: Interventional

This study is a randomized, double-blind, crossover trial aiming at evaluating the gastrointestinal tolerance of 3 sugar replacers mixes at 3 different doses. The investigators will also try to understand the factors that could explain the presence or absence of symptoms

NCT ID: NCT05644717 Not yet recruiting - Liver Fibrosis Clinical Trials

Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD

Ertu-NASH
Start date: March 1, 2023
Phase: Phase 4
Study type: Interventional

Open-label, prospective, single-arm, multicenter study to determine effects of Ertugliflozin on liver fat, liver fibrosis & glycemic control in subjects with Type 2 Diabetes Mellitus (T2DM) with Non-Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic Steatohepatitis (NASH)

NCT ID: NCT05592951 Completed - Safety Clinical Trials

Safety and Tolerability of a Novel Amino-acid Based Hydration Drink in Healthy Volunteers

Start date: September 30, 2022
Phase: N/A
Study type: Interventional

The nutrient composition of this product is similar to the existing Liquid IV "hydration multiplier" product already on the market but with the addition of amino acids. With such low quantities of amino acids, in particular as compared to the amounts consumed in normal diets, there is no reason to believe that the product would cause any adverse outcomes. However, since no research has been done on the safety of regular consumption of this product, this study will evaluate the safety of the product with regards to routing blood chemistries and other variables. Specifically, standard testing will be performed including a measurement of vital signs, comprehensive metabolic panel, hematology panel, urinalysis, and quantification of triiodothyronine, thyroxine, and thyroid stimulating hormone. A questionnaire will also be used to assess product tolerability.

NCT ID: NCT05585762 Completed - Aging Clinical Trials

Buck Institute Ketone Ester RCT

BIKE
Start date: November 28, 2022
Phase: N/A
Study type: Interventional

This study is to investigate the tolerability and safety of a ketone promoting ingredient, called a ketone ester (KE), in healthy older adults. This randomized, double-blind, placebo-controlled trial aims to characterize the tolerability and safety of daily consumption of the KE in healthy older adults (over 65 years old) over 12 weeks. Study participants will complete Beverage Tolerability Questionaires (BTQ) to rate any side side effects throughout the study. Safety will also be assessed by collection of blood and urine samples, vital signs, body weight, and monitoring of adverse events (AEs). The study will also collect pilot data to explore possible effects of KE on physical function, cognitive function and quality of life. The findings of this study will be used to facilitate future mechanistic studies of KE in aging.

NCT ID: NCT05542849 Completed - Tolerance Clinical Trials

The Efficacy and Tolerability of Acarbose in Healthy Individuals

Start date: August 10, 2022
Phase: Phase 4
Study type: Interventional

A Prospective Trial for Acarbose in Healthy Individuals Assessing Safety and Efficacy in Reducing Glucose Spikes After Carbohydrate Consumption.

NCT ID: NCT05527652 Recruiting - Clinical trials for Obstructive Sleep Apnea

Self-Supporting Nasopharyngeal Airway (ssNPA) Treating Upper Airway Obstruction in Hypotonia

Start date: November 16, 2022
Phase: N/A
Study type: Interventional

The researchers are investigating if the Self-Supporting Nasopharyngeal Airway (ssNPA) device can be used in the treatment of obstructive sleep apnea in children with Hypotonic Upper Airway Obstruction (HUAO).

NCT ID: NCT05428748 Not yet recruiting - Tolerance Clinical Trials

Clinical Trial to Evaluate Safety and Tolerability of a Novel Hydration Drink in Healthy Volunteers

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

This clinical trial design aims to evaluate the safety and tolerability of a novel hydration drink in health volunteers.

NCT ID: NCT05427253 Completed - Clinical trials for Pulmonary Hypertension

First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects

Start date: June 15, 2022
Phase: Phase 1
Study type: Interventional

This is a FIH, double-blind, placebo-controlled, within-group randomised, trial designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of single and multiple ascending oral doses of compound 106 (C106) in healthy females of non-childbearing potential and healthy males. The trial will be conducted in 2 parts: Part A, single ascending dose (SAD) including a food interaction cohort: safety, tolerability, and PK in healthy males and healthy females of non-childbearing potential receiving single ascending doses of C106. Part B, multiple ascending dose (MAD): safety, tolerability, and PK in healthy males and healthy females of non-childbearing potential receiving twice daily multiple ascending doses of C106 for 8 days.

NCT ID: NCT05382273 Completed - Cannabis Use Clinical Trials

Cannabis Tolerance Break Resource Study: T-Break Guide

Start date: April 22, 2021
Phase:
Study type: Observational

The purpose of this pilot study is to conduct research into the value of using the T-Break Guide for assisting people taking a tolerance break from cannabis. The hope is that this initial research will yield some insights and benchmarks into the Guide's efficacy, and provide a foundation for a later randomized control study. The following are some key research questions: 1. How did participants use the Guide? (Eg: daily; read once; 'a la carte') 2. How did using the Guide increase fidelity to tolerance break (starting, continuing, completing a break)? 3. Did using the Guide yield any benefits beyond tolerance break fidelity? (Eg: insight into patterns of use)

NCT ID: NCT05217732 Completed - Pharmacokinetics Clinical Trials

Study to Assess the Safety, Tolerability and Pharmacokinetics of ZX-7101A and the Food Effect in Healthy Volunteers

Start date: December 1, 2021
Phase: Phase 1
Study type: Interventional

Randomized, double-blind and placebo-controled study to assess the safety, tolerability and pharmacokinetics of single ascending doses of ZX-7101A and its food effect in China healthy adult volunteers. The study is composed of 2 parts. Part 1 is to assess the safety, tolerability and pharmacokinetics of a single ascending doses of ZX-7101A tablet. Part 2 is to assess the food effect on ZX-7101A at a selected dose in a cross-over design.